Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CLDINASDAQ:CTORNASDAQ:IMABNASDAQ:MDCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDICalidi Biotherapeutics$0.26-8.7%$0.40$0.23▼$3.89$8.27M1.07987,553 shs3.47 million shsCTORCitius Oncology$2.66+6.4%$1.06$0.55▼$4.42$178.88M-0.071.17 million shs1.74 million shsIMABI-Mab$2.37-3.7%$1.41$0.60▼$3.08$200.88M1.17362,762 shs280,737 shsMDCXMedicus Pharma$2.45+4.7%$4.19$1.80▼$8.94$31.76MN/A408,989 shs198,922 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDICalidi Biotherapeutics-8.74%-16.10%-36.62%-61.25%+26,009,900.00%CTORCitius Oncology+6.40%+83.45%+192.31%+315.63%+265,999,900.00%IMABI-Mab-3.66%-4.05%+139.39%+183.49%+37.79%MDCXMedicus Pharma+4.70%-4.67%-66.39%-27.08%+244,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDICalidi Biotherapeutics1.6629 of 5 stars3.53.00.00.00.60.00.6CTORCitius Oncology0.4014 of 5 stars2.00.00.00.00.01.70.0IMABI-Mab2.6178 of 5 stars3.74.00.00.00.61.70.6MDCXMedicus Pharma1.6972 of 5 stars3.80.00.00.01.80.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDICalidi Biotherapeutics 3.00Buy$10.003,744.68% UpsideCTORCitius Oncology 2.00Hold$3.0012.78% UpsideIMABI-Mab 3.33Buy$5.50132.07% UpsideMDCXMedicus Pharma 3.50Strong Buy$23.50859.18% UpsideCurrent Analyst Ratings BreakdownLatest CLDI, MDCX, CTOR, and IMAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.006/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/29/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/23/2025CTORCitius OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/23/2025CTORCitius OncologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/12/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $27.005/8/2025MDCXMedicus PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $20.004/28/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/21/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/14/2025MDCXMedicus PharmaD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDICalidi Biotherapeutics$50K165.39N/AN/A($2.32) per share-0.11CTORCitius OncologyN/AN/AN/AN/A$0.64 per shareN/AIMABI-Mab$3.89M49.75N/AN/A$2.47 per share0.96MDCXMedicus PharmaN/AN/AN/AN/A$0.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDICalidi Biotherapeutics-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/ACTORCitius OncologyN/AN/A0.00∞N/AN/A-53.88%-18.86%N/AIMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)MDCXMedicus Pharma-$11.16M-$1.16N/AN/AN/AN/A-380.03%-224.22%6/27/2025 (Estimated)Latest CLDI, MDCX, CTOR, and IMAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTORCitius Oncology-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A5/12/2025Q1 2025MDCXMedicus Pharma-$0.23-$0.42-$0.19-$0.42N/AN/A3/28/2025Q4 2024MDCXMedicus Pharma-$0.32-$0.18+$0.14-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDICalidi BiotherapeuticsN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDICalidi BiotherapeuticsN/A0.190.19CTORCitius Oncology0.110.360.05IMABI-MabN/A22.3522.35MDCXMedicus PharmaN/A1.531.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDICalidi Biotherapeutics12.53%CTORCitius Oncology70.52%IMABI-Mab38.38%MDCXMedicus PharmaN/AInsider OwnershipCompanyInsider OwnershipCLDICalidi Biotherapeutics6.70%CTORCitius Oncology4.57%IMABI-Mab22.10%MDCXMedicus PharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDICalidi Biotherapeutics3831.79 million20.04 millionN/ACTORCitius OncologyN/A71.55 million68.28 millionN/AIMABI-Mab38081.66 million63.61 millionOptionableMDCXMedicus PharmaN/A13.57 millionN/AN/ACLDI, MDCX, CTOR, and IMAB HeadlinesRecent News About These CompaniesD. Boral Capital Reaffirms "Buy" Rating for Medicus Pharma (NASDAQ:MDCX)June 25 at 1:51 AM | americanbankingnews.comMedicus Pharma appoints Andrew Smith as chief operating officerJune 24 at 10:30 PM | uk.investing.comMedicus Pharma appoints COO; updates on SKNJCT-003June 24 at 2:19 AM | thepharmaletter.comMedicus Pharma names Andrew Smith as COO, advances BCC and prostate drug studiesJune 23 at 8:59 AM | proactiveinvestors.comMedicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating OfficerJune 23 at 7:30 AM | newsfilecorp.comMedicus Pharma targets horse cancer with new trial – ICYMIJune 13, 2025 | proactiveinvestors.comMedicus Pharma targets horse cancer with new trial – ICYMIJune 13, 2025 | proactiveinvestors.comMedicus Pharma to Present at Bio Convention and Expand Cancer Treatment PortfolioJune 12, 2025 | tipranks.comMedicus Pharma Ltd. to Present at 2025 Bio International ConventionJune 12, 2025 | newsfilecorp.comMedicus Pharma submits FDA plan to develop microneedle-based treatment for skin cancer in horsesJune 9, 2025 | proactiveinvestors.comMedicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug ...June 9, 2025 | gurufocus.comMedicus Pharma Submits FDA Plan for Novel Equine Cancer TreatmentJune 9, 2025 | tipranks.comMedicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in HorsesJune 9, 2025 | newsfilecorp.comMedicus Pharma appoints KPMG as new auditor, expands global clinical programsJune 6, 2025 | proactiveinvestors.comMedicus Pharma completes $7 million public offeringJune 4, 2025 | uk.investing.comMedicus Pharma Ltd. Announces Closing of $7.0 Million Public OfferingJune 2, 2025 | newsfilecorp.comMedicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street ZenMay 31, 2025 | marketbeat.comD. Boral Capital Reiterates "Buy" Rating for Medicus Pharma (NASDAQ:MDCX)May 30, 2025 | marketbeat.comMedicus Pharma unveils pricing of $7M public offeringMay 30, 2025 | proactiveinvestors.comMedicus Pharma prices $7 million share offeringMay 30, 2025 | msn.comMedicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering | MDCX Stock NewsMay 29, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook3 Top-Rated Energy Companies Staging Strong RecoveriesBy Nathan Reiff | June 2, 2025View 3 Top-Rated Energy Companies Staging Strong Recoveries3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryWhy Goldman Sachs Suddenly Boosted These 3 Trucking StocksBy Gabriel Osorio-Mazilli | June 9, 2025View Why Goldman Sachs Suddenly Boosted These 3 Trucking StocksCLDI, MDCX, CTOR, and IMAB Company DescriptionsCalidi Biotherapeutics NYSE:CLDI$0.26 -0.02 (-8.74%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$0.26 0.00 (-1.58%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.Citius Oncology NASDAQ:CTOR$2.66 +0.16 (+6.40%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$2.88 +0.22 (+8.12%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.I-Mab NASDAQ:IMAB$2.37 -0.09 (-3.66%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$2.42 +0.05 (+1.94%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Medicus Pharma NASDAQ:MDCX$2.45 +0.11 (+4.70%) As of 06/24/2025 04:00 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
